{"title":"Hope in Wisdom Past and for Future Clinical Trials","authors":"Tracy A. Balboni MD, MPH, FAAHPM","doi":"10.1016/j.ijrobp.2025.04.030","DOIUrl":"10.1016/j.ijrobp.2025.04.030","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Pages 653-655"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James B Yu, David M DeStephano, Brian Jeffers, Alexander E Tward, Catherine S Spina, David P Horowitz, Tony J C Wang, Lisa A Kachnic, Pamela R Soulos, Cary P Gross, Simon K Cheng
{"title":"The Comparative Toxicity of Focal Ablation vs. IMRT for Prostate Cancer.","authors":"James B Yu, David M DeStephano, Brian Jeffers, Alexander E Tward, Catherine S Spina, David P Horowitz, Tony J C Wang, Lisa A Kachnic, Pamela R Soulos, Cary P Gross, Simon K Cheng","doi":"10.1016/j.ijrobp.2025.09.020","DOIUrl":"https://doi.org/10.1016/j.ijrobp.2025.09.020","url":null,"abstract":"<p><strong>Introduction: </strong>Focal ablative therapy (FT) aims to treat prostate cancer (PCa) with reduced toxicity compared to standard radiotherapy. There is an absence of studies comparing FT and Intensity Modulated Radiation Therapy (IMRT) for PCa.</p><p><strong>Methods: </strong>Using the SEER-Medicare database, we identified fee for service Medicare beneficiaries with PCa diagnosed from 2010-2017. Patients who underwent IMRT were Mahalanobis matched 2:1 to FT patients based on demographics, Medicaid eligibility, comorbidity, flu vaccination, primary care access, year, cancer characteristics, and androgen deprivation therapy. We used logistic regression models to assess the relation between treatment modality and presence of claims indicative of a gastrointestinal or genitourinary complication within 6, 12, and 24 months of treatment.</p><p><strong>Results: </strong>We identified 9,928 IMRT and 800 FT patients. After matching, patients treated with FT were less likely to have gastrointestinal toxicity (6.2%) within 12 months compared to IMRT patients (9.5%; Odds ratio [OR], 0.63 [95%CI 0.45-0.88]; results were similar at 24 months (11.0% FT vs. 21.5% for IMRT; OR 0.45 [95%CI 0.35-0.58]). Most gastrointestinal toxicity was due to diagnoses of rectal bleeding and colitis. In contrast, there were more claims indicative of genitourinary toxicity for FT compared to IMRT during the 0-12 (34.6% vs. 15.8%; OR 2.69 [95%CI 2.21-3.28]), and 0-24 (41.7% vs. 29.3%; OR 1.69 [95%CI 1.42-2.01]) month periods. The largest difference was in incontinence therapy (17.4% vs 7.5%, P<.01) and erectile dysfunction (18.2% vs. 13.1%, P<.01), favoring IMRT.</p><p><strong>Conclusion: </strong>Among older patients with prostate cancer, FT was associated with a higher risk of incontinence and impotence, compared to IMRT. There was more colitis and rectal bleeding with IMRT vs. FT, but related procedures were rare and not significantly different.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xinmin Liu, Ahmad Sakaamini, Wenbo Gu, Carl Denis, Michelle Alonso-Basanta, Rodney D Wiersma
{"title":"Performance of a Novel Frameless and Maskless Robotic Head Motion Compensation System for Stereotactic Radiosurgery in a Realistic Clinical Environment with Healthy Volunteers.","authors":"Xinmin Liu, Ahmad Sakaamini, Wenbo Gu, Carl Denis, Michelle Alonso-Basanta, Rodney D Wiersma","doi":"10.1016/j.ijrobp.2025.09.029","DOIUrl":"https://doi.org/10.1016/j.ijrobp.2025.09.029","url":null,"abstract":"<p><strong>Purpose: </strong>Stereotactic radiosurgery (SRS) is a non-surgical method for treating brain abnormalities and small tumors. Traditional high-accuracy SRS requires a rigid metal head frame screwed into the skull, which causes discomfort and reduces patient compliance. Thermoplastic masks offer a less invasive alternative but compromise accuracy due to flexing and are often still uncomfortable. To address these issues, we developed a novel robotic head motion compensation (RHMC) device that enables frameless and maskless SRS.</p><p><strong>Methods: </strong>A compact, portable RHMC device was developed that can be quickly attached to or detached from the end of a linear accelerator (Linac) treatment table. Real-time 6D head position tracking was performed using 3D surface-guided radiation therapy (SGRT) imaging, which was fed into the robot control computer. Device performance was evaluated by administering virtual SRS treatments to a phantom, and 20 healthy volunteers, simulating a clinical environment but without delivering radiation. The primary success metric was defined as maintaining the 6D target position under a 1.0mm and 1.0deg threshold for more than 95% of beam-on time (denoted as DC95%_1.0mm&1.0deg).</p><p><strong>Results: </strong>Two of the 20 volunteers were excluded due to incompatibility with the RHMC device. Among the remaining 18 volunteers, the DC95%_1.0mm&1.0deg success metric was achieved in all cases. Without RHMC, 9 of the 18 volunteers were able to meet this metric. For a tighter tolerance of DC95%_1.0mm&0.5deg, 17 volunteers achieved the metric with RHMC, compared to 4 without. For a tolerance of 1.0mm&1.0deg, across all 18 volunteers, the mean and range were 99% and 96-100% using RHMC, respectively, compared to 73% and 9-100% without RHMC.</p><p><strong>Conclusions: </strong>The RHMC device effectively maintained accurate head motion control under simulated clinical conditions, achieving the DC95%_1.0mm&1.0deg success metric for all suitable candidates. This technology has the potential to enable frameless and maskless SRS delivery within or better than current standard-of-care tolerance guidelines.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Icro Meattini MD, Charlotte E. Coles MRCP, FRCR, PhD, FMedSci
{"title":"Using Every Piece of the Jigsaw Puzzle to Optimize Treatment and Shared Decision-Making","authors":"Icro Meattini MD, Charlotte E. Coles MRCP, FRCR, PhD, FMedSci","doi":"10.1016/j.ijrobp.2025.05.005","DOIUrl":"10.1016/j.ijrobp.2025.05.005","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Pages 612-613"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145104156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In Regard to Lin et al","authors":"Jyotiman Nath MD","doi":"10.1016/j.ijrobp.2025.07.051","DOIUrl":"10.1016/j.ijrobp.2025.07.051","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"123 3","pages":"Page 910"},"PeriodicalIF":6.5,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}